The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Panitumumab, a fully human antibody targeting the epidermal growth factor receptor, is active in patients with metastatic colorectal cancer (mCRC). This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- and irinotecan-based) as first-line treatment for mCRC. Patients and Methods: Patients were randomly assigned within each chemotherapy cohort to bevacizumab and chemotherapy with or without panitumumab 6 mg/kg every 2 weeks. The primary end point was progression-free survival (PFS) within the oxaliplatin cohort. Tumor assessments were performed every 12 weeks and reviewed centrally. Results: A total of 823 and 230 patients were randomly assigned to the oxaliplatin and irinotecan cohorts, respectively. Panitumumab was discontinued after a planned interim analysis of 812 oxaliplatin patients showed worse efficacy in the panitumumab arm. In the final analysis, median PFS was 10.0 and 11.4 months for the panitumumab and control arms, respectively (HR, 1.27; 95% CI, 1.06 to 1.52); median survival was 19.4 months and 24.5 months for the panitumumab and control arms, respectively. Grade 3/4 adverse events in the oxaliplatin cohort (panitumumab v control) included skin toxicity (36% v 1%), diarrhea (24% v 13%), infections (19% v 10%), and pulmonary embolism (6% v 4%). Increased toxicity without evidence of improved efficacy was observed in the panitumumab arm of the irinotecan cohort. KRAS analyses showed adverse outcomes for the panitumumab arm in both wild-type and mutant groups. Conclusion: The addition of panitumumab to bevacizumab and oxaliplatin- or irinotecan-based chemotherapy results in increased toxicity and decreased PFS. These combinations are not recommended for the treatment of mCRC in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The PACCE study evaluated the addition of panitumumab to chemotherapy and bevacizumab, showing that the combined use of two biological agents may result in adverse outcomes irrespective of RAS mutation status [19].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Research works printed but not linked: 3
- Mitchell EP, 10th Annual World Congress of Gastrointestinal Cancers
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
- Ciardiello F, 2000, Clin Cancer Res, 6, 3739
Cited by
Sorted by citations
Items 801–849 of 849
Zhang, B., & Finn, R. S. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-56197-4_8
Liver Transplantation for Unresectable Disease
Line, P., Hagness, M., Solheim, J. M., Foss, A. E., & Dueland, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-13896-1_20
Molecular determinants of therapeutic response to targeted therapies in metastatic colorectal cancer
Weickhardt, A. J. (2011) · Minerva Access (University of Melbourne)
What Chemotherapy to Recommend in Metastatic Patients?
Stein, A., & Schmoll, H. (2017) · Springer eBooks · doi:10.1007/978-3-319-43217-5_43
Salem, M. E., Weinberg, B. A., Khalek, F. J. A., Desai, J. R., Warner, E. A., Hartley, M. L., & Marshall, J. L. (2019) · Springer eBooks · doi:10.1007/978-3-030-18890-0_8
Self-citationLiver Resection in Patients With Synchronous Colorectal Liver and Lung Metastases
Allison Horner, M., & Lencioni, K. (2016) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2016.7.7.9
Sequencing of Systemic Chemotherapy for Unresectable CRLM
Roth, M. T., & Goff, L. W. (2019) · Springer eBooks · doi:10.1007/978-3-030-25486-5_23
The efficacy of panitumumab in refractory metastatic colorectal cancer: A meta-analysis.
Duan, K., & Wang, H. (2019) · PubMed
Czito, B. G., & Willett, C. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1637-5.00048-1
Baszkowsky, L. S., Supko, J. G., & Chabner, B. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1637-5.00008-0
Chemotherapy and Targeted Drugs for Patients with Metastatic Colorectal Cancer
Pfeiffer, P., & Qvortrup, C. (2020) · Springer eBooks · doi:10.1007/978-3-030-58846-5_21
Eser, K. (2020) · International Journal of Hematology and Oncology · doi:10.4999/uhod.204659
Gastrointestinal Toxicities of Targeted Therapy
Chowdhury, T., Sukari, A. W., & Nagasaka, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-67241-2.00013-6
Orlovа, N. V., Ostroumova, O. D., Shikh, E. V., Smerdin, S., Rebrova, E. V., & Dyo, V. А. (2021) · Tuberculosis and lung diseases · doi:10.21292/2075-1230-2021-99-7-55-62
Kessler, E. R., Brittain, P., Davis, S. L., Leong, S., Eckhardt, S. G., & Lieu, C. H. (2017) · doi:10.1002/9781119468868.ch21
Gill, S., Brown, C. J., Miller, R. C., & Bathe, O. F. (2010) · Springer eBooks · doi:10.1007/978-3-642-13306-0_12
Heymach, J. V., Zurita‐Saavedra, A., Kopetz, S., Cascone, T., & Nilsson, M. B. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm017
Laheru, D. A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7358-0_18
(2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012462199
Rolfo, C. D., Bronte, G., Russo, A. D., & Peeters, M. (2013) · doi:10.2217/ebo.13.206
Sterrantino, C., Miroddi, M., Phillips, B., & Stewart, L. A. (2016) · International Journal of Cancer · doi:10.1002/ijc.30005
Raimundo, A. C. (2009) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000357534.05353.8c
Porschen, R. (2010) · Springer eBooks · doi:10.1007/978-3-642-11635-3_11
Tonini, G., Imperatori, M., Zoccoli, A., Iuliani, M., & Pantano, F. (2011) · doi:10.2217/ebo.11.98
Raimundo, A. C. (2009) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000357533.97728.af
A case of pulmonary thromboembolism occurring during chemotherapy for oral cancer
Shibata, A., Shimo, T., KISHIMOTO, K., Kunisada, Y., Mese, H., & Sasaki, A. (2022) · Japanese Journal of Oral & Maxillofacial Surgery · doi:10.5794/jjoms.68.193
Wan, Y., & Luo, D. (2022) · Research Square · doi:10.21203/rs.3.rs-1821994/v1
Li, G., Li, T. X., Fu, W., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00001-8
Liu, S., Ma, R., Cao, H., Yu, S., Chen, D., Jing, C., Wang, Z., Zhang, J., Feng, J., & Wu, J. (2019) · Oncology and Translational Medicine · doi:10.1007/s10330-018-0321-1
Son, I. T., Kim, M., Oh, B. Y., Kim, M. J., Yoon, S. N., Park, J. H., Kim, B. C., & Kim, J. W. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02937-7
Management of Metastic Liver Cancer
Stewart, C. L., Ho, F., Fong, Y., Davis, S. L., Lisa, L., Lindquist, J. D., Karukonda, P., Willett, C. G., & Czito, B. G. (2024) · Wiley eBooks · doi:10.1002/9781119756422.ch19
Bao, X., Chen, X., Qiu, J., Wang, D., Qian, X., & Sun, J. (2024) · Communications in computer and information science · doi:10.1007/978-981-97-0885-7_8
First Line Chemotherapy in Metastatic Colorectal Cancers: A Review
Colombo, A., Bordonaro, R., Sciacchitano, T., & Porretto, C. M. (2024) · International Journal of Advanced Multidisciplinary Research and Studies · doi:10.62225/2583049x.2024.4.2.2556
Therapeutic drug monitoring of selected anticancer drugs
Milone, M. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18649-3.00022-7
Tan, G., Liu, Y., Ye, W., Liang, Z., Lin, W., & Ding, F. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c02205
Li, Y., Du, Y., Xue, C., Wu, P., Du, N., Zhu, G., Xu, H., & Zhu, Z. (2022) · Figshare · doi:10.6084/m9.figshare.21310648
Additional file 1 of Exploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Figshare · doi:10.6084/m9.figshare.20330034
Bravo‐Valencia, L., & Rivera-Correa, M. (2011) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.204012
Li, Y., Du, Y., Xue, C., Wu, P., Du, N., Zhu, G., Xu, H., & Zhi, Z. (2022) · Figshare · doi:10.6084/m9.figshare.21310645
Yang, M., Schell, M. J., Salk, J. J., Higgins, J. E., Hipp, M. J., Pflieger, L. T., Pledger, W. J., & Yeatman, T. J. (2026) · Cellular Oncology · doi:10.1007/s13402-025-01140-y
Munster, A. B., Mahmood, U., Fuller, H., Seo, H., Murphy, J., Menon, K., Imber, C. J., Bhan, C., & Khan, K. H. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103139
SYNAPX: Explainable Anticancer Drug Synergy Prediction via SHAP Analysis
Kalaignan, Y., & Ding, Y. (2026) · IEEE International Conference on Big Data Computing Service and Applications (BigDataService) · doi:10.1109/bigdataservice70481.2026.00023
Anti-Angiogenic Monoclonal Antibodies
Oliveira, T. S., & Reis, A. R. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-6551-0.ch008
Tumeurs digestives : côlon — rectum
Bachet, J., Taı̈eb, J., Mitry, E., & Rougier, P. R. (2011) · Springer eBooks · doi:10.1007/978-2-8178-0021-9_23
Chemotherapie und systemische Therapie bei Lebermetastasen
Folprecht, G., Bokemeyer, C., Ståhl, M., Heinemann, V., Stemmler, H., & Wolf, M. (2010) · Springer eBooks · doi:10.1007/978-3-642-04935-4_40
Contemporary Evidence-Based Management of Newly Diagnosed Metastatic Colorectal Cancer
Raghav, K. P. S., & Eng, C. (2015) · American Journal of Hematology / Oncology®
Metadata
- Authors
- Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., Deeter, R., Shahin, S., & Amado, R. G.
- Affiliations
- Amgen (United States) (US)
- Venue
- Journal of Clinical Oncology
- Published
- 2009-02-10
- Volume
- 27
- Issue
- 5
- Pages
- 672-680
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2002226820
- Cited by
- 850
- References
- 30
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 19 · 2023: 10 · 2022: 21 · 2021: 15 · 2020: 29 · 2019: 29 · 2018: 26 · 2017: 38 · 2016: 44 · 2015: 57 · 2014: 56 · 2013: 88 · 2012: 101
- FWCI
- 53.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metastatic colorectal cancer, panitumumab, bevacizumab, oxaliplatin, irinotecan, EGFR inhibition, first-line chemotherapy, progression-free survival, treatment toxicity, KRAS mutation, anti-EGFR monoclonal antibody
- MeSH terms
- Bevacizumab, Irinotecan, Oxaliplatin, Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Colorectal Neoplasms, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
